Xeris Biopharma price target raised to $8 from $6.60 at H.C. Wainwright

H.C. Wainwright analyst Oren Livnat raised the firm’s price target on Xeris Biopharma (XERS) to $8 from $6.60 and keeps a Buy rating on the shares. The company’s first-time 2025 guidance for $255M-$275M in revenue is a “surprising” 11% above estimates and up 30% year-over-year at the midpoint, the analyst tells investors in a research note. The firm continues to view Xeris Biopharma as a top pick for 2025.